Capstone Investment Advisors
RCUS icon

Capstone Investment Advisors’s Arcus Biosciences RCUS Stock Holding History

Capstone Investment Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
+10,049
New +$248K ﹤0.01% 1442
2024
Q3 		– Sell
-21,847
Closed -$333K – 2150
2024
Q2 		$333K Buy
+21,847
New +$353K ﹤0.01% 1536
2024
Q1 		– Sell
-10,643
Closed -$203K – 2508
2023
Q4 		$203K Buy
+10,643
New +$170K ﹤0.01% 1793

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Capstone Investment Advisors's RCUS Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 10,049 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #1442 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in RCUS as recently as Q2 2024.

Capstone Investment Advisors first reported a position in RCUS in Q4 2023 and has held it in 3 quarters since. The position peaked at $333K in Q2 2024. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Capstone Investment Advisors held 10,049 shares of Arcus Biosciences worth $310K as of Q2 2026.
  • Arcus Biosciences was a new Capstone Investment Advisors position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1442 holding.
  • Capstone Investment Advisors first reported a position in Arcus Biosciences in Q4 2023 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Arcus Biosciences position peaked at $333K in Q2 2024.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.